Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225

Benzinga Newsdesk www.benzinga.com Negative 63.3%

Neg 63.3% Neu 0% Pos 0%

Piper Sandler analyst Adam Maeder maintains ResMed (NYSE:RMD) with a Neutral and lowers the price target from $233 to $225.